论文部分内容阅读
恶性胶质瘤虽然在肿瘤中所占比例低于2%,但是预后很差,特别是多形性胶质母细胞瘤的预后更差。即使给予胶质母细胞瘤患者有效的系统化疗,6个月无进展生存率仍不超过15%,复发后的中位总体生存时间为25周[1]。发病的年龄通常在四五十岁,这个年龄段的患者多为家庭的支柱,他们的过早死亡对家庭影响很大。因此,迫切需要找到更为有效的治疗方法。近年来,新型烷化剂替莫唑胺同期化放疗和替莫唑胺辅助化疗已成为新诊断
Although the proportion of malignant glioma in the tumor is less than 2%, the prognosis is very poor, especially the prognosis of glioblastoma multiform is worse. Even with effective systemic chemotherapy in glioblastoma patients, the 6-month progression-free survival rate still does not exceed 15% and the median overall survival after relapse is 25 weeks. The age of onset is usually four or five years old, this age group of patients are mostly the backbone of the family, their premature death has a great impact on the family. Therefore, there is an urgent need to find more effective treatments. In recent years, the new alkylating agent temozolomide concurrent radiotherapy and temozolomide adjuvant chemotherapy has become a new diagnosis